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Abstract 
The recent development of cellular models of mitochondrial DNA-linked diseases by transfer of patient-derived mitochondria nto 
human mtDNA-less ( p° ) cells has provided a valuable tool for investigating the complementation and segregation of mtDNA mutations. 
In transformants carrying in heteroplasmic form the mitochondrial tRNA Ly~ gene 8344 mutation or tRNA eeu°~vR) gene 3243 mutation 
associated, respectively, with the MERRF or the MELAS encephalomyopathy, full protection of the cells against the protein synthesis and 
respiration defects caused by the mutations was observed when the wild-type mtDNA exceeded 10% of the total complement. In the 
MERRF transformants, he protective ffect of wild-type mtDNA was shown to involve interactions of the mutant and wild-type gene 
products, probably coexisting within the same organelle from the time of the mutation event. In striking contrast, in experiments in which 
two mtDNAs carrying either the MERRF or the MELAS mutation were sequentially introduced within distinct organelles into the same 
pO cells, no evidence of cooperation between their products was observed. These results pointed to the phenotypic independence of the 
two genomes. A similar conclusion was reached in experiments in which a chloramphenicol (CAP) resistance-conferring mtDNA 
mutation was introduced into CAP-sensitive cells. In the area of segregation of mtDNA mutations, in unstable heteroplasmic MELAS 
transformants, observations were made which pointed to a replicative advantage of mutant molecules, leading to a rapid shift of the 
genome towards the mutant ype. These results are consistent with a model in which the mitochondrion, rather than the mtDNA molecule, 
is the segregating unit. 
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1. Introduction 
The discovery of the role of mitochondrial DNA 
(mtDNA) mutations in causing diseases in man (for a 
review see Ref. [1]) has opened new possibilities for basic 
research on mitochondrial genetics and mitochondrial 
molecular biology. Not only has this discovery made avail- 
able to the investigator a wealth of mtDNA mutations 
affecting mitochondrial genes at functionally critical sites, 
but it has also revealed the extraordinary complexity of the 
factors, both nuclear DNA- and mtDNA-encoded, that 
control the phenotypic manifestation of these mutations in 
the different tissues of an organism. It was a fortunate 
coincidence that novel genetic approaches for the manipu- 
lation of the human mitochondrial genome had been devei- 
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oped in our laboratory at about the same time as mtDNA- 
linked diseases were being discovered. These novel ap- 
proaches were based on the isolation of human cell lines 
that had been completely depleted of mtDNA by long-term 
exposure to low concentrations of ethidium bromide, and 
on the demonstration that these mtDNA-[ess (p° )  cells 
could be repopulated with exogenous human mitochondria 
of any source by functional complementation [2]. By trans- 
ferring into pO cells mitochondria from myoblasts or 
fibroblasts of patients affected by a mtDNA-l inked isease, 
it became thus possible to construct established cell lines 
carrying mutated mtDNA in a constant nuclear back- 
ground. 
The cellular models described above have turned out to 
be very valuable for investigating the molecular and bio- 
chemical pathogenetic mechanism of a mutation, for ana- 
lyzing the possible role of the nuclear background in the 
phenotypic manifestation of the mutation, and, finally, for 
studying the complementation a d segregation behavior of 
the mutated mtDNA when it co-exists with wild-type 
mtDNA. Several applications of this approach have al- 
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ready been made in our and other laboratories, which have 
yielded valuable information concerning the biochemical 
defects associated with several point mutations and dele- 
tions of mtDNA [3-6]. In this article, we will discuss 
recent experiments that have provided new insights into 
the rules that govern the complementation a d segregation 
of mtDNA in human cells. 
2. Complementation behavior of the MELAS and 
MERRF mutations in heteroplasmic pO cell transfor- 
mants 
The availability of a series of pO 206 cell transformants 
carrying the mitochondrial tRNA Leu(uUR) gene mutation at 
position 3243 associated with the MELAS encephalomy- 
opathy in heteroplasmic form, with varying proportions of 
mutant and wild-type mtDNA molecules derived from the 
same individual [6], has made it possible to investigate the 
capacity of wild-type mtDNA to complement the MELAS 
mutation by measuring the respiratory activity of the trans- 
formants. As shown in Fig. 1, there is a sharp threshold, 
around approx. 6%, in wild-type mtDNA proportion, above 
which this mtDNA protects against he phenotypic effect 
of the mutation, with full protection by approx. 10% 
wild-type mtDNA [6]. 
The striking complementing capacity of wild-type 
mtDNA is not a phenomenon unique to the tRNA Leu(UUR) 
3243 mutation, because a similar threshold in the protec- 
tive effect by wild-type mtDNA is observed for the tRNA Lys 
mutation at position 8344, which is associated with the 
MERRF encephalomyopathy [7]. Fig. 2a summarizes the 
relationship between proportion of wild-type mtDNA and 
respiratory capacity in different MERRF transformants 
tested at various times after their isolation. The diagram 
clearly illustrates the existence of a sharp transition, with a 
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Fig. l. A small amount of wild-type mtDNA can protect the mitochon- 
drial ,o ° 206 transformants against the respiratory defect caused by the 
MELAS mutation. The diagram illustrates the relationship between pro- 
portion of wild-type (WT) mtDNA and rate of 02 consumption i  
different heteroplasmic transformants (modified from Ref. [6]). 
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Fig. 2. A small amount of wild-type mtDNA can prevent the defective 
respiration (a and b) and protein synthesis (c) caused by the MERRF 
mutation i  different heteroplasmic p° 206 transformants, examined at
various times after mitochondria transfer (a), and in their subclones (b
and c) (from Ref. [7]). 
mid-point at a wild-type mtDNA proportion of approx. 
8%, in the ability of wild-type mtDNA to protect against 
the manifestation of the respiratory defect, with full protec- 
tion by 10% wild-type mtDNA. Fig. 2b shows that sub- 
clones of the MERRF transformants also exhibit a similar 
protective ffect of wild-type mtDNA against he pheno- 
typic expression of the MERRF mutation, but the mid- 
point-transition is displaced towards a 12% proportion of 
wild-type mtDNA, for unknown reasons. 
There are two possible interpretations for the protective 
effect of a small minority of wild-type mtDNA against he 
predominant mtDNA carrying the MELAS or MERRF 
mutation. The first is that approx. 10% wild-type mtDNA 
molecules are by themselves sufficient o provide the cells 
with normal respiratory capacity. The second interpretation 
is that the products of the 10% wild-type mtDNA interact 
with those of the 90% mutant mtDNA, complementing the 
defect(s) caused by the mutation. The availability of a 
molecular marker of the protein synthesis defect caused by 
the MERRF mutation allowed us to distinguish between 
the two alternatives mentioned above. This marker is an 
abnormal band, migrating slightly faster than ND4, which 
represents a premature translation termination product ob- 
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served consistently in cells carrying the MERRF 8344 
mutation in homoplasmic or near-homoplasmic form [3,8] 
(Fig. 3). The two alternative interpretations of the protec- 
tive effect of 10% wild-type mtDNA lead to two different 
predictions concerning the behavior of the abnormal band 
in transformants exhibiting varying ratios of mutant and 
wild-type mtDNA (Fig. 4). In fact, if 10% wild-type 
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Fig. 3. Pattern of mitochondrial translation products labeled with 
[35S]methionine for 1.3 h in the presence of 100 ~zg/ml emetine (a), and 
rate of O 2 consumption and cytochrome c oxidase activity (b) in pO cell 
mitochondrial transformants and, for comparison, in HeLa cells and 143B 
cells. The mitochondrial transformants were generated from pO 206 cells 
by fusion with cytoplasts derived from myoblasts of a MERRF patient 
(pTl to pT5) or of a normal individual (cTl). The pTl and pT4 
transformants contain the MERRF mutation in near-homoplasmic form, 
the pT2, pT3 and pT5 transformants lack the mutation. The asterisked 
band in the pT1 and pT4 lanes represents an abnormal translation product 
(from Ref. [31). 
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Fig. 4. Schematic representation f the predictions concerning the behav- 
ior of the abnormal mitochondrial translation product (asterisked), de- 
pending on whether the 10% wild-type mtDNA molecules are segregated 
in organelles distinct from those containing the 90% mutant molecules 
(Model I), or the 10% wild-type molecules are distributed among all the 
organelles within a cell, thus complementing the mutation in the hetero- 
plasmic organelles (Model II). Within the mitochondria, the shaded areas 
represent mutant (MT) mtDNA, the open areas, wild-type (WT) mtDNA. 
molecules are segregated in organelles distinct from those 
containing the 90% mutant molecules (Model I), and there 
is no interaction between the two types of genomes, one 
would expect that a cell having 100% mutant mtDNA 
would exhibit a very pronounced abnormal band, and a 
cell exhibiting 90% mutant and 10% wild-type mtDNA 
would also exhibit a strong abnormal band because of the 
lack of complementation f the mutation by the 10% 
segregated wild-type molecules. On the contrary, if the 
10% wild-type molecules are distributed among all or the 
majority of the organelles within a cell (Model II), they 
would complement the mutation in the heteroplasmic or- 
ganelles, thus preventing the formation of the abnormal 
band. The scheme of Fig. 4 shows, of course, two extreme 
situations, but serves to illustrate very well how dramati- 
cally different the phenotype of cells carrying 10% of 
wild-type mtDNA molecules can be depending upon the 
way these are distributed among the organelles. 
Fig. 2c shows the results of a quantification of the 
abnormal band in p° cell transformants carrying varying 
proportions of wild-type and mutant mtDNA. Again, there 
appears to be a sharp transition, with a mid-point at a 
wild-type mtDNA proportion of approx. 9%, above which 
the abnormal band decreases sharply in amount [7]. There- 
fore, the near-complete disappearance of the abnormal 
band parallels the recovery of respiratory capacity of the 
transformants. This result indicates that the threshold in the 
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protective ffect of wild-type mtDNA involves primarily 
the restoration of normal mitochondrial protein synthesis, 
and, as a consequence, the re-establishment of respiratory 
competence. Furthermore, and more importantly, the dis- 
appearance of the abnormal band strongly suggests that the 
protective ffect of wild-type mtDNA depends in major 
part on the intermixing and cooperation of the wild-type 
and mutant gene products. 
3. Lack of complementation of mtDNAs introduced 
separately into a cdl within distinct organelles 
The experiments described in the previous section 
clearly indicated that genome interactions occurred be- 
tween the MERRF mutant and wild-type mtDNAs trans- 
ferred from heteroplasmic myoblasts into p° cells. Two 
possible mechanisms could be invoked to explain these 
genome interactions. First, it is possible that the mutant 
and wild-type molecules of the heteroplasmic myoblasts 
coexisted within the same organelles as a result of the 
original mutation event, and that this intramitochondrial 
heteroplasmy was maintained uring the growth of the 
myoblasts and of the pO cell transformants derived there- 
from. It is indeed a plausible hypothesis that cells carrying 
heteroplasmic organelles would have a selective advantage 
due to the complementation f the mutation. A second 
possibility is that the mutant and wild-type mtDNA 
molecules were at least in part segregated within distinct 
organelles, but, as a result of a dynamic situation of 
mitochondrial fusion and division, there could be full 
intermixing and complementation between their products. 
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Fig. 5. Percentage of MERRF mtDNA, MELAS mtDNA and wild-type 
(WT) mtDNA in the double genome transforrnants and in the parental 
cell lines. The two-step cybrid clone 59 ×pT72-10, which was analyzed 
at two different times after fusion, 65 days (10A) and 114 days (10B), 
showed only the MERRF mutation atboth times (from Ref. [7]). 
In S. cerevisiae [9], Chlamydomonas pp. [10] and 
plants [11,12], there is good evidence of mitochondrial 
fusion and interorganellar genome interaction. In mam- 
malian cells, on the contrary, despite some suggestion [13], 
this phenomenon is far from being established. It seemed, 
therefore, important o test directly the capacity of mito- 
chondrial genomes carried in originally distinct organelles 
to interact with each other in the po transformants. For 
this purpose, advantage was taken of the ability to intro- 
duce sequentially into the same p° cell mitochondria 
carrying mtDNA with the MERRF 8344 mutation in the 
tRNA Ly~ gene and mitochondria carrying mtDNA with the 
MELAS 3243 mutation in the tRNA ceu(UUR) gene. The 
results presented in the previous section indicated that the 
two mutations are recessive, and therefore susceptible to 
complementation by the products of wild-type genes, if 
there are interactions between the mutant and wild-type 
genomes. 
For these experiments, two pO 206 transformants, 59 
and 2SD, derived from two genetically unrelated MELAS 
patients [6], and the p° 701.2a transformant pT72 [3], 
derived from a MERRF patient, were used to construct 
double transformants by two-step cybrid selection [7]. Fig. 
5 shows the genotype of the parental transformant lines 
and of the six two-step cybrid clones isolated during the 
selection of the double transformants. The two MELAS 
transformants exhibited only the tRNA Leu(UUR) mutation 
with a minimal amount of wild-type mtDNA, while the 
MERRF transformant carried only the tRNA Lys mutation 
with a negligible amount of wild-type mtDNA. Of the six 
two-step cybrid clones isolated, five exhibited both the 
MELAS and the MERRF mutation and a minimal amount 
of wild-type mtDNA. In the double transformants, the 
MELAS genome, carrying the wild-type tRNA Lys gene, 
was present in all cases in proportion greater than the 10% 
level previously shown to be required for complementation 
of the MERRF mutation; in particular, in four double 
transformants, it occurred in proportion between 28% and 
35%. 
Fig. 6 shows the results of experiments in which the 
level of mitochondrial protein synthesis and 02 consump- 
tion was measured in the parental transformant lines and in 
the two-step cybrid clones, examined between 42 and 99 
days after their isolation. It is clear that, in all MELAS- 
MERRF double transformants, there was a very low level 
of both mitochondrial protein synthesis and respiration. 
This result showed that, even after 3 months from the 
introduction of the second mutation, there was no evidence 
of cooperation between the products of the genomes carry- 
ing the MELAS mutation and of those carrying the MERRF 
mutation [7]. 
The results described above pointed clearly to the phe- 
notypic independence of the two genomes. A similar con- 
clusion was reached in another set of experiments, in 
which mitochondria from CAP23, a derivative of the hu- 
man cell line VA 2 B carrying in nearly homoplasmic form 
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Fig. 6. Quantification of the labeling of the mitochondrial translation 
products, after a 2 h [35S]methionine pulse (a), and of the rate of O, 
consumption in the double genome transformants and in the parental cell 
lines. The relatively high level of protein labeling and rate of 0 2 
consumption i  the parental line 2SD is, in part at least, accounted for by 
its very high mtDNA content (three times the 143B level) (from Ref. [7]). 
a chloramphenicol (CAP) resistance-conferring mitochon- 
drial DNA mutation [14], were introduced into the chlor- 
amphenicol sensitive 143B.TK-, therefore into the same 
nuclear background as that of the MERRF-MELAS double 
transformants previously analyzed [7]. In these experi- 
ments, cybrids containing varying proportions of CAW 
mtDNA exhibited a reasonably good proportionality be- 
tween the percentage of protein synthesis that was resistant 
to CAP and the percentage of CAP r mtDNA, in agreement 
with the assumption of a genetic independence of the 
CAP23-derived and 143B-derived mitochondria. Further- 
more, an electrophoretic variant (ND3') of the normal ND3 
gene product, synthesized in CAP23 cells as a result of a 
mtDNA mutation [15], exhibited in the cybrids an almost 
complete resistance to CAP, whereas synthesis of ND3 
was nearly totally sensitive to CAP. These results are again 
consistent with the phenotypic independence of the CAP r 
and CAP ~ genomes in the cybrids [7]. 
The fundamental conclusion of the experiments dis- 
cussed above is that interactions of mitochondrial genomes 
originally carried in distinct organelles occur rarely, if at 
all, in the cell lines analyzed here. Although the work 
described here has not addressed irectly the question of 
whether fusion took place between organelles carrying 
different mtDNA, the most plausible hypothesis that the 
lack of interactions between the two genomes reflected 
their physical segregation i  separate organelles, i.e., ab- 
sence of mitochondrial fusion. However, the results would 
also be compatible with the occurrence of mitochondrial 
fusion, if one assumed that the two genomes remained 
functionally segregated in different submitochondrial do- 
mains. The above conclusions have to be contrasted with 
the observation discussed previously of normal levels of 
mitochondrial protein synthesis and respiration in p° cell 
transformants derived from naturally occurring heteroplas- 
mic cells of a MERRF patient and containing more than 
10% wild-type mtDNA; they are also in contrast with the 
findings reported by others of a fusion protein [4] and of 
competition for tRNAs [16] in cybrids and, respectively, 
skeletal muscle segments carrying large mtDNA deletions. 
The most plausible interpretation of this discrepancy is 
that, in all the above-mentioned cases, in which there was 
obviously interaction of mutant and wild-type genomes, 
these coexisted in the same organelles from the time of the 
mutation. Although the observations reported above point 
to the phenotypic independence of mitochondrial genomes 
contained in distinct organelles in the cell lines analyzed 
here, they do not exclude that, in certain physiological or 
developmental situations, mitochondrial fusion and genome 
interactions may occur in mammalian systems. 
4. The significance of the 10% threshold for wild-type 
mtDNA protection against the MERRF tRNA Lys muta- 
tion 
The observations described above have clearly shown 
that the protection by 10% wild-type mtDNA against he 
phenotypic manifestation of the MERRF tRNA Ly~ muta- 
tion involves a complementation f the great majority, if 
not totality, of the mutant mtDNA molecules. This result is 
not inconsistent with previous observations concerning the 
cooperation between the products of wild-type and deleted 
mtDNAs in cybrids derived from cells of a patient affected 
by chronic external ophthalmoplegia (CPEO) [4]. In these 
cybrids, translational complementation f the tRNAs en- 
coded in genes included in the deleted mtDNA segment 
was observed when the wild-type mtDNA was >_ 40% of 
the total mtDNA. The apparent discrepancy between the 
10% wild-type mtDNA threshold for protection in the 
MERRF patient-derived p° cell transformants [7] and the 
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Fig. 7. MtDNA carrying the MELAS mutation rapidly replaces the wild-type (WT) mtDNA, or remains constant, during growth of different heteroplasmic 
p° cell transformants derived from MELAS patient 43, his asymptomatic maternally-related aunt (individual 94) and four other MELAS patients, 2S, 3E, 
4H, and 5 ×,  belonging to three different pedigrees. The curve 94B' was derived from analysis of another sample of early 94B cells. The genotype 
behavior of transformants 94L and 94I, carrying homoplasmic wild-type mtDNA, is also shown. The dotted portions of the curves represent interruptions 
in growth due to freezing and thawing of cells (from Ref. [17]). 
40% threshold observed in the CPEO patient-derived trans- 
formants is due to the fact that the mutant RNA Ly~ retains 
a substantial portion of its functional capacity. In fact, it 
has recently been shown that the tRNA Lys specific amino- 
acylation capacity per cell in pO cell transformants carry- 
ing the MERRF mutation is about 40 to 50% of that 
present in wild-type transformants (A. Enriquez and G. 
Attardi, unpublished ata), this aminoacylation deficiency 
being nevertheless ufficient o cause a severe impairment 
in mitochondrial protein synthesis (A. Enriquez, A. 
Chomyn and G. Attardi, unpublished ata). Therefore, the 
protective ffect by 10% wild-type mtDNA against the 
phenotypic manifestation of the MERRF mutation indi- 
cates that a relatively small amount of wild-type lysyl- 
tRNA Ly~ needs to be added to the substantial amount of 
aminoacylated tRNA Ly~ derived from the 90% mutant 
mtDNA to bring it to the protective level. It seems likely 
that the same situation will apply to other mitochondrial 
tRNA mutations affecting the tRNA functional capacity. 
5. Segregation behavior of the MELAS tRNA Leutl:UR) 
mutation 
The pO cell transformants carrying in heteroplasmic 
form the MELAS 3243 mutation in the tRNA t~utvUR) gene 
which were mentioned above were used to investigate the 
segregation behavior of mutant and wild-type mtDNAs 
upon prolonged subculturing [17]. As shown in Fig. 7, five 
of 13 clonal cell lines derived from individuals belonging 
to four pedigrees (94B, 2SE, 5 × 1, 3El, 3E7) were found, 
surprisingly, to undergo a rapid shift in their genotype 
towards the pure mutant ype. The other eight cell lines, 
that included two containing predominantly wild-type 
mtDNA (94H and 4H6) and six exhibiting nearly homo- 
plasmic mutant mtDNA (two of which (43B and 4HI) are 
shown in Fig. 7), maintained, on the contrary, a stable 
genotype. Subcloning experiments and growth rate mea- 
surements excluded a significant role of intercellular selec- 
tion of faster-growing mutant mtDNA-enriched cells in the 
genotype shift observed in the unstable heteroplasmic 
MELAS transformants. Therefore, the most reasonable 
interpretation f these data is that a replicative advantage 
of mutant mtDNA molecules over wild-type molecules 
was the main factor responsible for the observed genotype 
shift. This interpretation extends the phenomenon of 'sup- 
pressiveness' to a higher eukaryote mtDNA with a point 
mutation. Suppressiveness was originally described in yeast 
for a subclass of 'petite' mtDNA mutations [18], and, 
subsequently, in Neurospora and other filamentous fungi 
for senescence processes leading to the replacement of 
normal mtDNA with grossly abnormal mtDNA [19-21]. 
As to the mechanism of the suppressiveness detected in 
MELAS mutation-carrying mtDNA, neither a smaller size 
of the mutant mtDNA molecules [22], nor, presumably, the 
loss of cis-acting control elements [16], factors that have 
been previously considered to explain the accumulation of
mtDNA molecules with large deletions in mtDNA-linked 
diseases, could play a role. The occurrence of transfor- 
mants (94H and 4H6 in Fig. 7) that did not exhibit an 
amplification of the mutant mtDNA over a period of 5-6 
weeks would tend to exclude any selective mechanism 
acting at the level of individual mtDNA molecules, point- 
ing on the contrary to a mechanism involving selection at 
the level of individual organelles. One plausible such 
mechanism would involve a feedback phenomenon that 
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Fig. 8. Model illustrating the proposed role of intermitochondrial versus 
intramitochondrial heteroplasmy in determining the selective amplifica- 
tion of the mutant genomes. Within the mitochondria, the shaded areas 
represent mutant rntDNA, the open areas, wild-type mtDNA. 
induces the selective replication of mtDNA in mito- 
chondria functionally compromised by the presence of 
mutated mtDNA [17]. This possibility has been raised 
before to account for the preferential accumulation of 
deleted or otherwise grossly altered mtDNA [16,21]. Such 
a mechanism would imply that the nucleo-cytoplasmic 
compartment has the capacity of sensing which organelles 
are functionally deficient, perhaps because of their defi- 
cient ATP production and resulting under-phosphorylation 
of some membrane component, and would by feedback 
stimulate the replication of mtDNA in such organelles. In 
view of the complementing capacity for the MELAS muta- 
tion of even a small minority of wild-type mtDNA, segre- 
gation of the mutant mtDNA in pure form in separate 
organelles may be the critical factor controlling the replica- 
tive advantage of the defective mtDNA molecules. This 
model is illustrated schematically in Fig. 8. According to 
this model, any physiological or developmental situation 
which would favor mitochondrial division may produce 
the segregation of pure mutant mtDNA molecules (inter- 
mitochondrial heteroplasmy), this resulting in preferential 
replication of such molecules. Since there is a constant 
number of mtDNA replication events per cell cycle [23], 
any hyper-replication f mutant mtDNA would cause un- 
der-replication of wild-type molecules, and thus produce 
the observed genomic shift. By contrast, any physiological 
or developmental condition which would slow down mito- 
chondrial division relative to organeilar growth or, possi- 
bly, promote mitochondrial fusion, would favor the coexis- 
tence in the same organelle and possibility of interactions 
of mutant and wild-type mtDNAs (intramitochondrial het- 
eroplasmy). This would result in a cell having heteroplas- 
mic organelles fully competent, and therefore functionally 
indistinguishable from homoplasmic wild-type organelles, 
and thus prevent the replicative advantage of defective 
mtDNA molecules from being manifested. Transformants 
94H and 4H6 may represent examples of such a situation. 
6. Implications for mtDNA-linked diseases and aging 
processes 
The experiments described in this article and the con- 
cepts developed herein have touched upon fundamental 
questions concerning the phenotypic manifestation of dis- 
ease-causing mtDNA mutations and the transmission and 
progression of these diseases. Thus, the evidence indicat- 
ing that the way in which mutant mtDNA molecules are 
sorted among the organelles (intra- vs. inter-organellar 
heteroplasmy) can play a crucial role in the phenotypic 
expression of the mutation has clear relevance to the 
extraordinary tissue specificity of the dysfunctions caused 
by disease-causing mutations and to the frequent poor 
correlation between severity of clinical symptoms and 
proportion of mutant mtDNA. Since mitochondrial organi- 
zation is under nuclear control and varies among different 
cell types and in different stages of development, it is a 
very plausible idea that this organization is an important 
parameter that can affect the expression of a mutation in 
different issues. 
The observation reported here of MELAS transformants 
in which the mutant mtDNA has a replicative advantage 
over wild-type mtDNA has potential important implica- 
tions for understanding the forces operating in the inheri- 
tance and progression of mtDNA-linked diseases. It has 
still to be established whether the observed replicative 
advantage of mutant mtDNA molecules is somehow linked 
to the particular nature of the MELAS mutation, or whether 
it reflects a more general behavior of defective mtDNA. 
However, it seems possible that the clonal expansion of the 
single deletion events early in development that produces 
the accumulation of deleted mtDNA molecules [24], the 
hyperreplication f mutant mtDNA molecules observed in 
'ragged red fibers' in mitochondrial myopathies [16,25], 
and the shift in genotype towards higher proportions of 
mutant mtDNA in successive generations of some LHON 
[26-28] and MELAS pedigrees [29] reflect the operation 
of the same mechanism for replicative advantage of mutant 
mtDNA molecules proposed here. 
The model illustrated in Fig. 8 is based on the concept 
that the unit of segregation of the mitochondrial genome in 
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mammalian cells is the organelle rather than the individual 
mtDNA molecule. There is other evidence in the literature 
that supports the idea that different types of mtDNA 
originally located in separate organelles tend to remain 
segregated in mammalian cells, including the gradual elim- 
ination of HeLa cell mtDNA in hybrids of HeLa cells and 
fibroblasts [30,31] and the complete switch, in only one or 
a few generations, of mtDNA genotypes in Holstein cows 
[32,33]. In the latter system, the observations indicating 
that the rapidity of segregation of mitochondrial alleles 
within heteroplasmic oocytes can vary are consistent with 
a model assuming that the kinetics of segregation is influ- 
enced by whether the individual organelles are homoplas- 
mic or heteroplasmic [34]. 
The observations presented here concerning the comple- 
mentation and segregation behavior of disease-causing 
mtDNA mutations are also relevant to an understanding of
the possible role that the accumulation with age of somatic 
mtDNA mutations has in the decline in respiratory activity 
observed in various tissues of aging individuals [35,36]. In 
fact, because of the expected random nature of the aging- 
related mtDNA mutations, it is reasonable to raise the 
question of whether and to what extent complementation 
of these mutations by the predominant wild-type alleles 
would tend to mask their phenotypic manifestation. On the 
other hand, under the hypothesis of the genetic indepen- 
dence of the organelles, the deficiencies of these organelles 
would be expected to be additive, and possibly amplified 
as a result of the selective replication of their mtDNA 
molecules. It is clear that an answer to these questions will 
be essential for an understanding of the contribution of any 
age-related mtDNA damage to the aging processes. 
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